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Introduction
Tumour markers have been employed for the diagnosis
and monitoring of cancer patients for many years. In
urology, PSA is assessed in patients with prostate cancer
and AFP and hCG in patients with testicular germ cell
tumours. These markers are characterised by relatively
high sensitivity and specificity, although they do fail to
meet the criteria of “an ideal marker”, and until now, the
urinary bladder cancer marker has not been identified.
Cancer of the urinary bladder shows a distinctive
prevalence in men. The standardised mortality index
classified the bladder cancer as the second most common
malignancy of the genito-urinary tract [1].
The diagnosis and monitoring of patients with
bladder cancer are based upon an invasive technique, the
cystoscopy. A urinary marker is extensively searched for
as a potential, easily-accessible, low-cost screening tool.
The identification of a specific and sensitive marker
could limit the number of cystoscopies performed for
monitoring and follow-up purposes. In the recent studies
telomerase, the bladder tumour antigen (BTA) and
nuclear matrix protein-22 (NMP22) [2-9] were examined
in the urine of bladder cancer patients. The authors
assessed not only the relationships between the markers
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I n t r o d u c t i o n.  The aim of this study was to evaluate the clinical use of the urinary nuclear matrix protein 22 (NMP22)
assessment in bladder cancer patients.
Pa t i e n t s  a n d  m e t h o d s.  98 patients with bladder cancer were examined. All tumours were verified histopathologically.
Urine samples were collected before cystoscopy and assayed for NMP22 levels with Diagnostic Products Corporation tests.
Urine samples of 15 healthy volunteers served as controls. For the statistical analysis the Mann-Whitney test was employed.
R e s u l t s.  Urine NMP22 concentrations were significantly higher (p<0.0003) in patients with bladder cancer than in
controls. No significant differences between the NMP22 concentrations in patients with complete remission and patients with
recurrent disease were found.
C o n c l u s i o n s.  Urinary NMP22 is a potential marker for the diagnosis of bladder cancer, but not for the differentiation
between disease-free patients and those with recurrent disease.
Ocena przydatnoÊci oznaczania NMP22 w moczu
jako markera nowotworowego u chorych na raka p´cherza
W s t ´ p.  Celem pracy by∏o zbadanie, czy oznaczanie markera nowotworowego NMP22 mo˝e byç pomocne w monitorowa-
niu chorych na raka p´cherza.
Pa c j e n c i  i m e t o d y.  Do badania zakwalifikowano 98 chorych z potwierdzonym histologicznie rakiem p´cherza. Próbki
moczu pobierano przed cystoskopià. St´˝enie NMP22 w moczu oznaczano zestawami firmy DPC. W∏asne normy ustalono
w oparciu o oznaczenia st´˝eƒ NMP22 w grupie 15 zdrowych osób. Do analiz statystycznych zastosowano test Mann-Whitney’a.
W y n i k i. Porównujàc rozk∏ad st´˝eƒ NMP22 w grupie chorych na raka p´cherza z grupà referencyjnà osób zdrowych,
stwierdzono znamiennie wy˝sze st´˝enia u osób chorych (p<0,0003). Nie stwierdzono znamiennych ró˝nic pomi´dzy st´˝enia-
mi NMP22 u chorych z ca∏kowità remisjà, a st´˝eniami tego markera u chorych ze wznowà.
W n i o s k i.  Oznaczanie markera NMP22 mo˝e byç pomocne tylko w diagnostyce ró˝nicujàcej osoby z rakiem p´cherza od
osób zdrowych, natomiast nie ró˝nicuje chorych w remisji od chorych z nawrotem choroby.
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and the clinico-pathological features of the tumours but
also the possibility of applying the markers for monitoring
of patients [2, 6, 7, 10]. The results of numerous studies on
NMP22 were contradictory and difficult to compare due
to the different cut-off levels applied.
In the study presented here, we set our own normal
urine NMP22 range and aimed to assess whether there is
a significant relationship between urine NMP22 concen-
trations and the results of urinary bladder cystoscopic
examinations.
Materials and methods
Ninety eight patients with pathologically confirmed urinary
bladder cancer were studied after they had undergone TURT
(TransUrethral Resection of Tumor, one procedure in 36 and
numerous procedures in 62 patients). Patients with a second
primary malignancy, with any signs of infection and/or with
lithiasis were excluded from the study. In 94 cases the stage of
the disease was determined, and the grade of malignancy in 95
cases. Patient characteristics is summarised in Table I.
Table I. Patient characteristic
Number of patients: 98
Men 84
Women 14
Median of age and range:
Men 67 (36-96)
Women 63.5 (38-89)
T:
Ta 39/94
Tis 2/94
T1 42/94
T2 9/94
T3 2/94
Histology:
G1 28/95
G2 59/95
G3 8/95
Clinical stage:
CR (clinical remission) 79
PD (progressive disease) 19
Urine samples were obtained just before control cystoscopy
and stored in stabilizing solution at – 20°C until analysed.
NMP22 concentration was assessed with the DPC kits following
the instructions of the manufacturer. Normal NMP22 range was
set in 15 healthy volunteers.
The non-parametric Mann-Whitney test was employed to
examine the distribution of NMP22 concentrations in patients
and controls and to compare the results obtained in patients in
remission and with progressive disease.
Results
Urine NMP22 concentrations were found significantly
higher in patients with bladder cancer than in healthy
subjects (p<0.0003, Figure 1). Also patients in remission
as well as those with recurrent disease presented
significantly higher urine NMP 22 concentrations than
healthy controls (p<0.0003 and p<0.001, respectively,
Figure 2, 3).
No statistically significant differences of NMP22
concentrations were found between patients in remission
and those with recurrent disease (Figure 4).
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Figure 1. Comparison of NMP22 concentrations in healthy subjects
(controls) and bladder cancer patients
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Figure 2. Comparison of NMP22 concentrations in healthy subjects
(controls) and disease-free bladder cancer patients
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Figure 3. Comparison of NMP22 concentrations in healthy subjects
(controls) and bladder cancer patients with recurrent disease
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Figure 4. Comparison of NMP22 concentrations in bladder cancer
patients in remission and with recurrent disease
Out of 79 patients with cystoscopically confirmed
remission, urine NMP22 concentrations fell within the
normal range in 36, thus correlated with their clinical
status. In the remaining 43 patients, despite cystoscopic
remission, the NMP22 concentrations were increased. Of
these 43 patients, 5 presented recurrent disease within
the following 4-12 months.
In 19 patients with cystoscopically confirmed
recurrent disease urine NMP 22 level was increased in
10 cases, while in 9 patients NMP22 concentrations fell
within the normal range, thus did not relate to their
clinical status.
Discussion
Bladder cancer morbidity increases with age. It is
a frequently recurrent disease, and the risk of repeated
recurrences is increased in patients who had experienced
recurrence within the first year following diagnosis
[11, 12]. Due to the growing incidence and frequent
recurrence of this malignancy, as well as because of the
relatively high costs of cystoscopy applied as a routine
diagnostic and monitoring method, there is a need for
less costly and non-invasive diagnostic tools. Tumour
markers are likely candidates to serve this purpose.
In our study, in order to assess the relationship
between cystoscopy results and NMP22 urine concen-
trations, we have paid a special attention to the followed-
up patients. In both groups of patients, in remission and
with recurrent disease, concentrations of NMP22 did in
fact confirm the cystoscopic findings in only half of the
cases. Similar results have been reported by other authors
[13, 14].
Some authors suggest that increased NMP22 con-
centrations may have a prognostic value [2]. In our study,
the observation period was too short to conclude on the
prognostic value of urine NMP22 levels in bladder cancer
patients. However, in 5 patients who had developed
recurrent disease in 4-12 months after complete remission
assessed by cystoscopy, the elevated NMP22 concen-
trations preceded the relapse.
A number of authors have attempted to set the
optimal cut-off level in order to increase specificity. Thus
the sensitivity of the applied markers was decreased. This
would enable their better relevance in monitoring of
treatment [7, 15]. Glas et al. [8] in an extensive paper
summarise the results of a multi-centered long-term study
on the sensitivity and specificity of BTA, NMP22 and
telomerase and they do not recommend the use of any of
these markers in clinical practice due to their limited
specificity. Some other authors recommend the use of
a combination of NMP22 assessment and cytology
examination in bladder cancer patients [7].
Conclusions
In conclusion, both the literature data and our own results
show that the analysis of urine NMP22 concentrations
cannot reduce the number of cystoscopies performed in
bladder cancer patients. This parameter may only provide
an additional information for differentiating between
healthy individuals and patients with bladder cancer.
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